Amalgamated Bank increased its position in Allergan plc (NYSE:AGN) by 9.7% during the 4th quarter, HoldingsChannel.com reports. The fund owned 42,285 shares of the company’s stock after buying an additional 3,735 shares during the period. Amalgamated Bank’s holdings in Allergan were worth $6,917,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Ascend Capital LLC bought a new position in Allergan in the 4th quarter worth $4,805,000. Hudson Bay Capital Management LP bought a new position in shares of Allergan during the 4th quarter worth about $3,272,000. First City Capital Management Inc. bought a new position in shares of Allergan during the 4th quarter worth about $545,000. BancorpSouth Bank bought a new position in shares of Allergan during the 4th quarter worth about $1,268,000. Finally, Spark Investment Management LLC bought a new position in shares of Allergan during the 4th quarter worth about $3,157,000. Hedge funds and other institutional investors own 79.66% of the company’s stock.
Several research analysts have recently issued reports on the stock. Leerink Swann boosted their price objective on shares of Allergan from $237.00 to $242.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Vetr downgraded shares of Allergan from a “buy” rating to a “hold” rating and set a $180.97 price objective on the stock. in a report on Wednesday, January 10th. Argus downgraded shares of Allergan from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $256.80 to $160.07 in a report on Thursday, December 7th. Wells Fargo & Co restated an “outperform” rating and set a $245.00 price objective (down previously from $258.00) on shares of Allergan in a report on Thursday, November 2nd. Finally, Royal Bank of Canada dropped their price objective on shares of Allergan from $250.00 to $221.00 and set an “outperform” rating on the stock in a report on Thursday, November 2nd. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $225.94.
Allergan plc (AGN) opened at $159.91 on Wednesday. The company has a market cap of $54,750.00, a PE ratio of -13.34, a price-to-earnings-growth ratio of 1.15 and a beta of 1.19. Allergan plc has a 12-month low of $156.00 and a 12-month high of $256.80. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 1.06.
Allergan (NYSE:AGN) last released its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 EPS for the quarter, beating the Zacks’ consensus estimate of $4.74 by $0.12. The firm had revenue of $4.33 billion for the quarter, compared to analyst estimates of $4.28 billion. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.43%. The company’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same period in the previous year, the business earned $3.90 earnings per share. equities research analysts predict that Allergan plc will post 15.58 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th will be given a $0.72 dividend. The ex-dividend date is Tuesday, February 27th. This is a positive change from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 dividend on an annualized basis and a yield of 1.80%. Allergan’s payout ratio is -23.35%.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.